Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax + Acalabrutinib vs Immunochemotherapy in Newly Diagnosed CLL/SLL
NCT06319456Phase 3Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Apr 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lisaftoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Ascentage Pharma. Started Apr 2024; status: recruiting.
02
Drugs
lisaftoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06319456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06319456.